Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A new two-monthly HIV prevention injection, cabotegravir, is recommended for NHS use in England and Wales to help end new HIV cases by 2030.
A long-acting injectable HIV prevention drug, cabotegravir (Apretude), has been recommended for use on the NHS in England and Wales, offering a two-monthly alternative to daily oral PrEP.
The treatment is for adults and adolescents at high risk of HIV who face barriers to daily pills due to medical, lifestyle, or social challenges.
Approved by NICE, it will be available through sexual health clinics, with rollout expected within months.
The NHS secured a discount on the drug, which has a list price of about £7,000 per year.
Officials say it could help the UK reach its goal of ending new HIV transmissions by 2030.
While PrEP use in England rose to 111,000 people in 2024, disparities persist, especially among Black African heterosexual men and women.
Advocates urge rapid expansion beyond clinics to improve equity.
The injection must be used with safer sex practices.
Early research suggests future annual options may be possible.
Una nueva inyección bimensual de prevención del VIH, cabotegravir, se recomienda para el uso del NHS en Inglaterra y Gales para ayudar a poner fin a los nuevos casos de VIH para 2030.